Quote:
Originally posted by sgtclub
This raises a very important philosophical point that gets at the heart of the issue - who is to decide how much R&D/profit is too much? I am far more comfortable with each enterprise making that determination based on market incentives that the decision be regulated by the government.
|
I am too, but drug companies aren't facing true "market" incentives right now, so to say that changing the current regulation is pareto inferior is not a forgone conclusion.
I don't think it would be too unreasonable , if one has a national Rx drug plan, to offer a price that is equal to an exchange-rate adjusted average price in the 7 largest industrial countries other than the US.
